Vortioxetine's post-marketing safety profile determined through cluster analysis of global adverse event reports

被引：0
|
作者：
Ekhart, Corine [1 ]
van Hunsel, Florence [1 ]
van Puijenbroek, Eugene [1 ,2 ]
Chandler, Rebecca [3 ]
Meldau, Eva-Lisa [3 ]
Noren, Niklas [3 ]
机构：
[1] Netherlands Pharmacovigilance Ctr Lareb, Shertogenbosch, Netherlands
[2] Univ Groningen, Groningen, Netherlands
[3] Uppsala Monitoring Ctr, Uppsala, Sweden
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
4070
引用
收藏
页码：497 / 497
页数：1
相关论文
共 50 条
  • [31] Paediatric post-marketing pharmacovigilance: comparison of the adverse event profile of vigabatrin prescribed to children and adults
    Aurich-Barrera, Beate
    Wilton, Lynda
    Brown, David
    Shakir, Saad
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (06) : 608 - 618
  • [32] Mining of adverse event signals associated with inclisiran: a post-marketing analysis based on FAERS
    Shi, Xuezhong
    Qiao, Ying
    Yang, Yongli
    Wang, Nana
    Zhang, Yi
    Shi, Shangxin
    Shen, Guibin
    Jia, Xiaocan
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [33] Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system
    Zhu, Zhou
    Liu, Mingjuan
    Zhang, Hanlin
    Zheng, Heyi
    Li, Jun
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [34] Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
    Zhao, Dan
    Zhang, Wangxin
    Liu, Yan
    Yan, Zhaojun
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [35] The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data
    Cohen, Russell D.
    Bhayat, Fatima
    Blake, Aimee
    Travis, Simon
    JOURNAL OF CROHNS & COLITIS, 2020, 14 (02): : 192 - 204
  • [36] Post-marketing safety concerns with montelukast: A pharmacovigilance study based on the FDA adverse event reporting system
    Ou, Zhimin
    Han, Ying
    Zhuang, Wei
    Xiao, Yunshan
    Cai, Shuying
    Zhang, Xueqin
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2024, 62 (11) : 497 - 506
  • [37] Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
    Xiong, Rui
    Lei, Jing
    Pan, Sicen
    Zhang, Hong
    Tong, Yongtao
    Wu, Wei
    Huang, Yi
    Lai, Xiaodan
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [38] Post-Marketing Safety of ALK inhibitors: An Analysis of EudraVigilance reports Between 2012 and 2022
    Lipovec, Nanca Cebron
    Knez, Lea
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 306 - 307
  • [39] Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database
    Jiang, Tingting
    Li, Yanping
    Zhang, Ni
    Gan, Lanlan
    Su, Hui
    Xiang, Guiyuan
    Wu, Yuanlin
    Liu, Yao
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2025, 16
  • [40] Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system
    Fu, Xiang
    Zeng, Dongqiang
    Li, Min
    Wu, Jianhua
    Yang, Yufan
    Mao, Qianqian
    Qiu, Wenjun
    Huang, Xiatong
    Fang, Yiran
    Jiang, Luyang
    Hu, Panwei
    Wu, Jiani
    Liao, Wangjun
    EXPERT OPINION ON DRUG SAFETY, 2025,
12345